ISSCA Announces the Lineup of Speakers for the Regenerative Medicine World Congress 2023
International Society for Stem Cell Application presents an unparalleled gathering of experts in Istanbul, Turkey.
Miami, Florida – The International Society for Stem Cell Application (ISSCA) is thrilled to unveil the remarkable roster of speakers for the highly anticipated Regenerative Medicine World Congress 2023. Set to take place from November 10 to 12, 2023, at the exquisite Crowne Plaza Istanbul Florya Hotel in Istanbul, Turkey, the congress is primed to be a convergence of minds dedicated to the advancement of stem cell therapy and regenerative medicine.
With over 35 countries represented, the Regenerative Medicine World Congress 2023 promises to be an extraordinary platform for knowledge exchange and scientific exploration. Distinguished doctors and scientists from across the globe will unite to discuss the latest developments in stem cell therapy and regenerative medicine through evidence-based research presentations.
Delegates attending the congress will have the unique opportunity to engage with more than 25 world-renowned medical experts who will present their insights and findings on a spectrum of issues related to this groundbreaking field. This three-day event is designed to foster interactive sessions, enabling attendees to deepen their understanding and broaden their perspectives on the applications of stem cell technology in various medical conditions.
Dr. Salih Yildirim, President of ISSCA, expressed his enthusiasm, saying, “I am delighted to witness the convergence of global medical experts in Istanbul. The Regenerative Medicine World Congress 2023 is an occasion to showcase our commitment to fostering international collaboration, sharing knowledge, and propelling medical progress.”
Echoing this sentiment, Benito Novas, an esteemed figure in the realm of regenerative medicine and the head of Public Relations for GSCG and ISSCA, highlighted ISSCA’s mission: “Our aim at ISSCA is to facilitate an environment of global collaboration and knowledge exchange. The Regenerative Medicine World Congress 2023 epitomizes this objective, offering a unique opportunity for professionals to engage in critical discussions, share insights, and collectively contribute to the advancement of medical science.”
A central highlight of the congress is the immersive hands-on training, facilitated by distinguished ISSCA-certified instructors. Participants will embark on an in-depth exploration of clinical and aesthetic applications of stem cell therapy during an intensive single-day workshop on November 12th. This comprehensive training, designed exclusively for those who secure the all-access package (limited to 20 seats), is guided by experts with extensive experience. Attendees are expected to acquire tangible skills that are readily applicable in their medical practice.
The congress will be inaugurated by Dr. Dayeong Kim from Korea and the President of ISSCA, Dr. Salih Yildirim. Their opening address will set the tone for an array of engaging sessions led by esteemed experts. Topics will span diverse medical conditions and real-world case studies, showcasing the application of stem cell therapy across various contexts.
Among the impressive lineup of speakers are luminaries such as:
– Dr. Dayeong Kim (Korea)
– Dr. Salih Yildirim (Turkey)
– Dr. Alan Gaveck (USA)
– Dr. Serdar Kabatas (Turkey)
– Dr. Yanti Kushmiran (Indonesia)
– Dr. Hilmi Karadeniz (Turkey)
– Dr. Roni Moya (Portugal)
– Dr. Tunç Akkoç (Turkey)
– Dr. Erdinc Civelek (Turkey)
– Dr. Mehmet Veli Karaaltın (Turkey)
– Dr. Ayman El Attar (USA)
– Prof. Utku Ates (Turkey)
– Dr. Fikrettin Şahin (Turkey)
– Dr. Emel Polat (Turkey)
– Dr. Patria Gonzalez (Dominican Republic)
– Dr. Ferda Alpaslan Pinarli (Turkey)
– Dra. Silvina Pastrana (Argentina)
– Dr. Samy Joheir (Belgium)
– Dr. Ahmet Doğan (Turkey)
– Dr. Jorge Elias (Argentina)
– Dr. Roland Neff (Switzerland)
– Prof. Aygen Türkmen (Turkey)
The Regenerative Medicine World Congress 2023 is an unparalleled opportunity for professionals to enrich their expertise, expand their network, and stay at the forefront of cutting-edge advancements in the field. To register and access detailed event information, please visit https://www.issca.us/turkey-world-conference-2023/
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine.
The mission of the International Stem Cell Certification Agency (ISSCA) is to establish itself as a global leader in regenerative medicine certification, education, research, and training.
ISSCA provides certification training in cities worldwide because it recognizes the importance of standards and certifications in regenerative medicine as a medical specialty. To help more people, both locally and globally, as the demand for more doctors interested in and comfortable with regenerative medicine surges. ISSCA’s mission is to advance quality and uniformity in regenerative medicine worldwide.
About Global Stem Cells Group:
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement:
Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Release
Global Stem Cells Group (GSCG) and Dr. Yanti Aesthetic Clinic Elevate Regenerative Medicine Landscape with New Stem Cell Center in Jakarta
Miami, Florida – Global Stem Cells Group (GSCG) is thrilled to announce the grand opening of its latest state-of-the-art Stem Cell Center, located in Jakarta, Indonesia. This momentous occasion marks a significant stride forward in the field of regenerative medicine and showcases GSCG’s commitment to providing innovative healthcare solutions worldwide.
In a groundbreaking partnership with the esteemed Dr. Yanti Aesthetic Clinic, GSCG introduces its third Stem Cell Center in Indonesia, complementing existing facilities in Surabaya and Bandung. Further underscoring their dedication to advancing medical research, GSCG also anticipates the unveiling of a fourth location in Bali in the near future.
The launch of the Stem Cell Center in Jakarta serves as a beacon of innovation, the International Society for Stem Cell Application (ISSCA), GSCG’s educational division, conducted a groundbreaking training session alongside Dr. Alan Gaveck. This session spotlighted the transformational potential of NK cell therapies in treating Cancer and Anti-aging concerns, further cementing GSCG’s pioneering influence.
A distinctive feature of this collaboration is the authorization granted to Dr. Yanti Aesthetic Clinic to leverage GSCG’s brand, technologies, products, and treatment protocols. Operating as a franchise, the center proudly carries the brand, adhering to meticulous organizational guidelines, while being owned and operated by Dr. Yanti Aesthetic Clinic. This symbiotic arrangement seamlessly merges shared expertise with individual ownership, fostering a harmonious blend of vision and innovation.
Beyond its role as a clinical hub, the newly inaugurated Stem Cell Center will also serve as a focal point for ISSCA’s training initiatives in Asia. In addition to the pioneering NK cell therapy training conducted at the clinic, the center will facilitate educational programs to empower medical professionals across the continent with cutting-edge insights and advancements in regenerative medicine.
Benito Novas, an esteemed figure in the realm of regenerative medicine and the head of Public Relations for GSCG and ISSCA, shared his insights during the inaugural event, stating, “Global Stem Cells Group is dedicated to democratizing regenerative medicine access on a global scale. We encourage physicians to embrace the clinical and aesthetic applications of stem cell therapy, enabling patients around the world to experience the transformative benefits of regenerative treatments.”
Reflecting on the journey that led to this momentous occasion, Novas continued, “Dr. Yanti and I met in Brussels back in 2018, when this ambitious endeavor was but a vision. Today, as we witness the fruition of that vision, I express my profound gratitude for the privilege of collaborating with Dr. Yanti Aesthetic Clinic in ushering in the future of regenerative medicine.”
Dr. Yanti Kushmiran, Director of the DR. Yanti Aesthetic Clinic, echoed these sentiments, stating, “Our partnership with GSCG, a trailblazer with over a decade of pioneering work, resonates deeply with our commitment to excellence. The establishment of our third Stem Cell Center in Indonesia under the esteemed Global Stem Cells Group brand strengthens our ability to provide enhanced services to our patients, ushering in a new era of regenerative healthcare.”
With the inauguration of the Stem Cell Center in Jakarta, GSCG and Dr. Yanti Aesthetic Clinic take a significant stride towards advancing regenerative medicine’s frontiers. This landmark collaboration is poised to shape the future of medical care, leveraging cutting-edge technologies and expertise to benefit patients across the Asian continent and beyond.
About Dr. Yanti Aesthetic Clinic:
Dr. Yanti Aesthetic Clinic is a revered healthcare institution renowned for its state-of-the-art aesthetic and regenerative treatments. With an unwavering dedication to excellence and a forward-thinking approach, Dr. Yanti Aesthetic Clinic is poised to shape the future of regenerative medicine in Indonesia and beyond.
About the International Society for Stem Cell Application (ISSCA):
The International Society for Stem Cell Application (ISSCA) serves as the educational arm of Global Stem Cells Group (GSCG), dedicated to promoting knowledge and expertise in stem cell therapy and regenerative medicine. ISSCA empowers medical professionals across the globe with essential insights and advancements in the field.
About Global Stem Cell Group
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Release
Global Stem Cells Group Announces New President of the International Society for Stem Cell Application (ISSCA)
Miami, Florida – Global Stem Cells Group, a leading organization in the field of regenerative medicine, is pleased to announce the appointment of Dr. Salih Yildirim as the new President of the International Society for Stem Cell Application (ISSCA), a division of Global Stem Cells Group. Dr. Yildirim previously held the position of Director of Overseas Operations at ISSCA.
Dr. Salih Yildirim brings a wealth of experience and expertise to his new role as President of ISSCA. Having previously served as the Director of Overseas Operations, Dr. Yildirim has demonstrated his exceptional leadership skills and strategic vision throughout his career. He has played a vital role in expanding ISSCA’s international presence and fostering collaborations with stakeholders worldwide.
In a statement regarding the appointment, Dr. Daeyong Kim, the former President of ISSCA, expressed his confidence in Dr. Yildirim’s ability to lead the organization. Dr. Kim stated, “I think you are the best leader and the most prepared to be the President of ISSCA. Therefore, I think you should be the head of ISSCA.” Dr. Kim will now transition to other support functions within ISSCA.
Benito Novas, head of Public Relations for ISSCA, expressed his admiration for Dr. Salih Yildirim’s professional qualities. Novas said, “I have known and worked with Dr. Salih for more than 10 years, and I am honored to have him as President within the company. During these years, he has proven to be an exceptional leader with a great vision for ISSCA.”
ISSCA’s objectives under the leadership of Dr. Salih Yildirim will include advancing the understanding and application of stem cell therapies, promoting scientific research and collaboration among professionals in the field, and advocating for the ethical and responsible use of regenerative medicine worldwide. Dr. Yildirim’s extensive experience in business development, international relations, and regenerative medicine will undoubtedly contribute to the achievement of these objectives.
About Dr. Salih Yildirim:
Dr. Salih Yildirim holds a bachelor’s and master’s degrees in business administration from Cleveland State University (United States) and a Ph.D. in health management from the University of Health Sciences. He has held various key positions throughout his career, including Director of Overseas Operations at ISSCA. Dr. Yildirim is currently the General Manager of BioTrend Medical International, a biotechnology firm specializing in genetics, molecular biology, and stem cell technologies. He also serves as the chief executive officer of ReGen.IC Clinic, specializing in regenerative medicine and stem cell applications. Additionally, he is a member of the International Society for Stem Cell Application’s Board of Directors and the Global Stem Cell Group’s Board of Directors and International Operations Manager. Dr. Yildirim is also a member of Istanbul Atlas University’s Board of Directors. He is married and a proud father.
About ISSCA
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and regenerative medicine.
ISSCA updates its members on advances in stem cell research, MSC, exosomes, and regenerative medicine
The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.
The international community provides a platform for practitioners to interact with scientists and build medical networks necessary for marketing.
As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities worldwide. The goal is to encourage more physicians to practice regenerative medicine and make it available to patients nationally and internationally. Incorporated under the Republic of Korea as a non-profit company, the ISSCA is focused on fostering excellence and standards in regenerative medicine.
About Global Stem Cells Group
Global Stem Cells Group is the parent company of six companies that are dedicated to stem cell research, solutions, and technology training. The group was founded in 2012 and combines dedicated researchers, patient educators, and physician trainers with the shared goal of meeting the need for high-end stem cell solutions and treatments.
Given that the group has a singular focus in this field, it is uniquely positioned to become the global leader in cellular medicine. In addition, by bringing together leading professionals in cellular medicine, it can discover issues that the industry faces and focus its research and development in this area. This specialization has, undoubtedly, enabled it to come up with solutions that address some of the significant issues that most stakeholders are facing in the industry.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Release
International Society for Stem Cell Applications Launches Advanced Turkish Hair Transplant Certification Program in Cancun
Miami, Florida – The International Society for Stem Cell Applications (ISSCA) is thrilled to announce the launch of its newest program, the Advanced Turkish Hair Transplant Certification. This pioneering training and certification initiative will take place from December 8th to 10th at the prestigious Cellular Hope Institute Facility in Cancun, Mexico. Physicians are encouraged to register promptly as the program is expected to fill up quickly.
Turkey has earned a global reputation for providing the finest hair transplants worldwide. Some of the hair transplant experts from Turkey who have developed and perfected this procedure are now willing to share their secrets with any physician who seeks to excel in hair restoration procedures in their home country. The demand for hair regrowth, hair restoration, and hair transplant procedures is growing by the day as men and women realize they do not have to suffer from the embarrassment of thinning hair and bare scalps anymore.
The Advanced Turkish Hair Transplant Certification program offers a comprehensive curriculum encompassing cutting-edge hair transplant procedures. Participants will engage in both theoretical and practical training sessions, helping to assist their mastery of this rapidly expanding field. They will have the extraordinary opportunity to practice hair transplant surgeries under the supervision and guidance of world-renowned experts in the field, including Veysel Cabalar, Asli Uslu, and Emere Tuncinar, who bring their wealth of experience and knowledge to the program.
In addition to hair transplant surgery, the program’s curriculum will cover workshops on advanced hair restoration techniques such as exomes, stem cells, and platelet-rich plasma treatments. Participants will learn how to select suitable patients for these different hair restoration methods and gain hands-on experience in preparing, storing, and administering exosomes, stem cells, and platelet-rich plasma to promote hair regrowth. Armed with this expertise, we believe participants will return to their own clinics with confidence, ready to deliver these transformative procedures for the benefit of their patients.
Dr. Salih Yildirim, ISSCA President, expressed his delight in fulfilling the organization’s mission of expanding the reach of new regenerative medicine technologies to doctors and patients worldwide: “The Advanced Turkish Hair Transplant Certification program exemplifies our commitment to advancing the field of regenerative medicine. We are proud to provide doctors with the tools and knowledge to bring the latest hair restoration techniques to their patients.”
Benito Novas, ISSCA Vicepresident , added, “We are excited to bring this groundbreaking Turkish training to Cancun, offering local doctors and physicians across Latin America the opportunity to learn from the best. Our collaboration with the Cellular Hope Institute Facility underscores our dedication to providing exceptional educational experiences that benefit medical professionals and patients alike.”
The program will include theoretical sessions on scalp and hair follicle anatomy, patient evaluation, and surgical preparation for hair transplant procedures. Detailed workshops on graft extraction and implantation techniques will also be conducted, enabling participants to refine their skills and achieve realistic, outstanding results. From patient evaluations to postoperative care protocols, the hands-on surgical sessions will encompass every aspect of the hair transplant process.
The Advanced Turkish Hair Transplant Certification program by ISSCA offers an invaluable opportunity for doctors seeking to excel in the field of hair transplantation. Participants will gain comprehensive knowledge, refine their surgical techniques, and stay abreast of the latest advancements in hair regrowth, hair restoration, and hair transplants.
To learn more about the Advanced Turkish Hair Transplant Certification program and register for this transformative educational experience, please visit the official ISSCA website at www.issca.com.
About ISSCA
The International Society for Stem Cell Applications (ISSCA) is a multidisciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through advances in regenerative medicine. By bringing together worldwide researchers and healthcare practitioners, ISSCA aims to bridge the gap between cutting-edge scientific research and compassionate, effective patient care.
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a world-renowned leader in regenerative medicine, specializing in innovative solutions that harness the power of stem cells for therapeutic applications. With a global network of offices and an unwavering commitment to excellence, GSCG continues to shape the future of regenerative and restorative medicine through groundbreaking products and advanced treatment protocols.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Release
Global Stem Cells Group (GSCG) is Proud to Announce Its Latest Cellgenic Exosome Product
Global Stem Cells Group (GSCG), a renowned leader in regenerative medicine, is thrilled to unveil its groundbreaking product, Cellgenic Lyophilized Exosomes – The Regen Series. We believe this product is set to revolutionize orthopedic and pain management applications, offering a remarkable potential for tissue regeneration in damaged areas of the body. Derived from human umbilical cord mesenchymal stem cells, Cellgenic Lyophilized Exosomes is a multifaceted solution that holds promise in addressing a wide range of ailments.
Cellgenic Lyophilized Exosomes contain a synergistic blend of essential components, including peptides, coenzymes, minerals, amino acids, vitamins, and UV radiation-reducing agents. These elements not only facilitate tissue regeneration but also make this product an exceptional option for skin revitalization. By utilizing this remarkable product, individuals may experience reduced pain levels.
A Revolutionary Product
Cellgenic Lyophilized Exosomes demonstrate unparalleled versatility and efficacy. Notably, this product requires no special storage conditions, enabling customers to utilize it conveniently at full capacity. Designed to combat inflammation and facilitate tissue repair, this targeted solution can significantly alleviate chronic pain, providing relief to those who have struggled to find effective solutions.
The exosome technology utilized in this product involves the freeze-drying of extracellular vesicles (EVs), which are kept separate from the mesenchymal stem cell cultures expanded in the laboratory. The Lyophilized Exosomes are then reconstituted with saline in front of the patient, just before use. This approach has proven to be highly effective in reducing inflammation and managing pain.
Global Stem Cells Group Remains a Leader in the Industry
One of the things that has helped set Global Stem Cells Group apart from the competition is their willingness to think in innovative ways that others simply do not. For example, the brand-new Lyophilized Exosome product can be shipped anywhere around the world without refrigeration. This allows for the possibility of getting it out to the places that truly need it without the burdensome ordeal of having to maintain the medication at a certain temperature. This is a problem for many medications, but GSCG has made sure that its products are more versatile than that.
Growing Faster Than Ever Before
Global Stem Cells Group has a lot going for it as far as its growth trajectory is concerned. They already have multiple offices around the globe, and they are always looking to expand their outreach by opening offices wherever it is prudent to do so. We believe the new product, Lyophilized Exosomes – The Regen Series, is set to strengthen GSCG’s position as a global leader in the regenerative and restorative medicine space for now and long into the future.
Benito Novas, CEO of Global Stem Cells Group, expressed his excitement about the company’s growth and stated, “Our goal at Global Stem Cells Group is to develop the most effective regenerative products on the market. Our new product line of lyophilized exosomes is a testament to our commitment to developing cutting-edge products with great clinical utility.”
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a world-renowned leader in regenerative medicine, specializing in innovative solutions that harness the power of stem cells for therapeutic applications. With a global network of offices and an unwavering commitment to excellence, GSCG continues to shape the future of regenerative and restorative medicine through groundbreaking products and advanced treatment protocols.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Release
Global Stem Cells Group and ReGen Form Strategic Partnership to Advance Regenerative Care Worldwide
Global Stem Cells Group, a leader in the field of regenerative medicine, proudly announces an innovative partnership with ReGen, a highly acclaimed Turkish clinic renowned for its cutting-edge technologies in aesthetic and regenerative care. This strategic alliance exemplifies Global Stem Cells Group’s commitment to advancing the field of regenerative medicine and expanding global access to transformative treatments.
As a trailblazer in the industry, Global Stem Cells Group actively seeks strategic partnerships with companies and organizations that share its vision of advancing regenerative care. The collaboration with ReGen signifies a remarkable milestone in this endeavor.
A Solid Partnership
ReGen, a highly regarded clinic specializing in advanced regenerative care technologies, has joined forces with Global Stem Cells Group to facilitate the expansion of franchising opportunities for specialized regenerative care clinics worldwide. By harnessing the collective strengths of both organizations, this partnership aims to cultivate an environment where their shared expertise and services can flourish, delivering regenerative healthcare solutions to individuals across the globe.
Rapid Growth
Through the partnership, ReGen has experienced remarkable growth, leveraging the Global Stem Cells Group’s name and resources to open two state-of-the-art clinics in Buenos Aires, Argentina, and Cancun, Mexico. These clinics have established themselves as pioneers in the field of regenerative care, surpassing existing alternatives in the region.
By introducing cutting-edge aesthetic treatments such as the perfected hair transplant technique from Turkey, ReGen is revolutionizing the landscape of regenerative healthcare. The clinics now offer patients access to the latest and most effective treatment options available. ReGen’s ability to bring their expertise to new regions underscores Global Stem Cells Group’s vision of making their exceptional services accessible to individuals worldwide.
The Trained Expert Behind ReGen
Leading the way at ReGen is Dr. Salih Yildirim, an esteemed CEO with a visionary mindset committed to spearheading a paradigm shift in the realm of regenerative medicine. Driven by an unwavering passion to extend the benefits of cutting-edge aesthetic technologies hailing from Turkey, encompassing areas such as hair transplantation, rhinoplasty, mammoplasty, and stem cell treatments, he has taken the momentous decision to expand the global presence of ReGen clinics. This strategic alliance with the esteemed Global Stem Cells Group aims to grant greater accessibility to Turkey’s esteemed aesthetic and regenerative medicine treatments, catering to a broader spectrum of patients.
Evident in this initiative is ReGen’s resolute dedication to disseminate its advanced techniques and state-of-the-art technologies across the globe, thereby propelling progress in the field of regenerative medicine.
How Global Stem Cells Group Can Improve ReGen’s Reach
While ReGen brings its advanced techniques and expertise to the partnership, Global Stem Cells Group offers a range of valuable resources. As a conglomerate of companies engaged in product manufacturing and comprehensive training through the International Society for Stem Cell Application (ISSCA), Global Stem Cells Group enhances the partnership’s outreach and impact. This collaboration has the potential to be life-changing for individuals seeking regenerative care worldwide.
Dr. Yildirim expresses his satisfaction with the partnership, stating, “We are delighted to join forces with Global Stem Cells Group. This collaboration allows us to establish additional points of care globally, furthering the accessibility of stem cell applications and advancing regenerative medicine.”
This milestone partnership between Global Stem Cells Group and ReGen is destined to reshape the world of regenerative care. It represents a turning point that will be remembered as a transformative moment for the field of regenerative medicine.
Benito Novas, CEO of Global Stem Cells Group, emphasizes the significance of this alliance, stating, “Our collaboration with Dr. Yildirim spans several years, and he has consistently demonstrated exceptional leadership and humility. By incorporating the ReGen program into the Global Stem Cells Group umbrella, which encompasses products manufacturing, ISSCA training, and centers of excellence for point-of-care regenerative medicine, we continue to solidify our commitment to excellence.”
As this partnership evolves, both organizations will continue to work tirelessly to develop new treatments, enhance existing procedures, and ensure the highest standards of patient care. Through their joint efforts, they will accelerate the adoption of regenerative care practices on a global scale, creating a ripple effect that will benefit patients and healthcare providers alike.
For more information about Global Stem Cells Group and its regenerative medicine solutions, please visit https://www.stemcellsgroup.com/.
About Global Stem Cells Group
Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.
About ReGen
ReGen is a highly acclaimed Turkish clinic renowned for its expertise in cutting-edge technologies related to regenerative care. Headquartered in Istanbul, ReGen has gained international recognition for its commitment to excellence and its groundbreaking advancements in regenerative medicine. By partnering with Global Stem Cells Group, ReGen aims to share its advanced techniques and expertise on a global scale, improving access to regenerative care and transforming lives worldwide.
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Release
ISSCA launched its first regenerative medicine training in Hormonal Modulation and Gynecology
Miami, Florida – The International Society for Stem Cell Application (ISSCA), a division of Global Stem Cells Group (GSCG), successfully launched its inaugural training course in Hormonal Modulation and Gynecology, marking a significant milestone in the field of regenerative medicine. The course, held from June 10-12, 2023, in Cancun, Mexico, generated immense enthusiasm among participants as the Global Stem Cell Group demonstrated its commitment to disseminating cutting-edge training and information to medical professionals worldwide.
Led by a Well-Respected Doctor
Under the guidance of Dr. Jorge Alberto Elias, a renowned Gynecologist and Urogynecologist with over a decade of experience in Cellular Therapies, participants had the privilege of learning from a highly respected expert in the field. His expertise ensured that attendees received valuable and up-to-date information, enhancing the quality of their educational experience.
The event was divided between two esteemed venues, with the theoretical portion taking place at the Four Points Hotel, and the hands-on training conducted at the prestigious Cellular Hope Institute.
ISSCA commitment to advancing regenerative medicine was further demonstrated by the inclusion of over 30 doctors who joined the event remotely, accessing the conferences and the live proceedings through online channels. This approach enabled medical professionals worldwide to be part of the educational experience, even if they couldn’t attend in person. By embracing technology, the company expanded the reach of knowledge dissemination and fostered a global community of practitioners dedicated to staying at the forefront of regenerative medicine.
The training program focused on equipping doctors and medical professionals with the latest advancements in regenerative medicine, with a specific emphasis on gynecology. Participants delved into the cutting-edge techniques and breakthrough procedures that are shaping the field.
Three Days of Intense Learning
The three-day program was divided into theoretical sessions and hands-on practical training. The theoretical portion took place at the Four Points Hotel, where participants delved into the intricacies of hormonal modulation and its application in gynecology. Dr. Silvina Pastrana, director of ISSCA education in Latam, complemented the program with a session on Exosomes, stem cells, and automatic closed processing techniques using the GCell machine, providing a comprehensive overview of the latest advancements.
During the practical segment, participants convened at the Cellular Hope Institute, where they were immersed in real-life scenarios and witnessed the application of regenerative measures in gynecological cases. Seven diverse cases were presented, including Labiaplasty, Perineum Vaginoplasty, Lichen Sclerosus, Liposuction Mount of Venus, and Lipo fat transfer with open and closed techniques. Through these hands-on demonstrations, attendees gained practical skills and insights into utilizing regenerative medicine to enhance patients’ quality of life.
Reflecting on the success of the event, Benito Novas, Head of Public Relations for the International Society for Stem Cell Application, expressed his enthusiasm, stating, “We are delighted to further expand the ISSCA faculty and specialty areas, opening the door for all physicians to utilize the latest Regenerative Medicine technologies in their area of expertise. Our goal is to provide the best education and training in regenerative medicine and cellular therapies so that professionals can offer the highest quality care to their patients.”
ISSCA celebrates the tremendous success of this inaugural regenerative medicine training course and remains committed to expanding access to the latest knowledge and advancements in the field. By empowering medical professionals globally, ISSCA aims to help patients worldwide benefit from the latest strategies and breakthroughs in regenerative medicine.
About ISSCA
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and regenerative medicine.
ISSCA updates its members on advances in stem cell research, MSC, exosomes, and regenerative medicine
The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.
The international community provides a platform for practitioners to interact with scientists and build medical networks necessary for marketing.
As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities worldwide. The goal is to encourage more physicians to practice regenerative medicine and make it available to patients nationally and internationally. Incorporated under the Republic of Korea as a non-profit company, the ISSCA is focused on fostering excellence and standards in regenerative medicine.
About Global Stem Cells Group
Global Stem Cells Group is the parent company of six companies that are dedicated to stem cell research, solutions, and technology training. The group was founded in 2012 and combines dedicated researchers, patient educators, and physician trainers with the shared goal of meeting the need for high-end stem cell solutions and treatments.
Given that the group has a singular focus in this field, it is uniquely positioned to become the global leader in cellular medicine. In addition, by bringing together leading professionals in cellular medicine, it can discover issues that the industry faces and focus its research and development in this area. This specialization has, undoubtedly, enabled it to come up with solutions that address some of the significant issues that most stakeholders are facing in the industry.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Release
ISSCA Announces Its Next World Congress 2023: The Premier Regenerative Medicine Event of the Year
The International Society for Stem Cell Application (ISSCA) is excited to announce the much-anticipated World Congress 2023, further establishing its role as the primary global hub for regenerative medicine. The event is set to occur from November 10 to 12, 2023, at the esteemed Crowne Plaza Istanbul Florya Hotel in Istanbul, Turkey. Drawing on the remarkable achievements of the previous conference held at the Radisson Blu Hotel on September 23 to 26, 2022, ISSCA is prepared to exceed all predictions with this highly anticipated World Congress.
During the three-day congress, prominent physicians from across the globe will come together, offering an extensive agenda of presentations and interactive sessions. “Our ISSCA Congresses once more provide a great opportunity to disseminate this information to the physicians who need it most, and we plan to organize as many as we can before the end of the year,” says ISSCA Managing Director and CEO of Global Stem Cells Group Benito Novas about the upcoming congress.
Participants can anticipate captivating workshops, including those focused on aesthetic and clinical applications, aimed at delving into the most recent advancements within the rapidly evolving field of regenerative medicine.
In a full schedule of lectures, the congress will shed light on significant subjects such as molecular biology, innovative treatment approaches in surgical and cosmetic domains, and the latest cutting-edge technologies that have emerged in the field. In addition, the congress will explore the legal framework encompassing regenerative medicine practices on a global scale, acknowledging the varying degrees of involvement by various national governments.
This conference demonstrates ISSCA’s dedication to facilitating a transformative change from traditional healthcare methods to regenerative medicine while showcasing the most recent innovative discoveries and progress in all aspects of stem cell research.
The Crowne Plaza Istanbul Florya Hotel, known for its modern facilities and ideal location in Istanbul, Turkey, will serve as the prestigious venue for this highly anticipated event. Its comfortable and conducive environment provides the optimum platform for attendees to exchange ideas and establish new partnerships.
The ISSCA World Congress 2023 in Istanbul is a must-attend event for anyone interested in regenerative medicine. With a focus on innovation, collaboration, and knowledge exchange, the congress promises to be a transformative experience for all attendees. Whether you are a scientist, physician, or healthcare professional, this event offers an opportunity to gain valuable insights and forge new connections with like-minded individuals from around the world.
For more information about the November 10 to 12 ISSCA World Congress 2023, please visit our official website today.
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine.
The mission of the International Stem Cell Certification Agency (ISSCA) is to establish itself as a global leader in regenerative medicine certification, education, research, and training.
ISSCA provides certification training in cities worldwide because it recognizes the importance of standards and certifications in regenerative medicine as a medical specialty. To help more people, both locally and globally, as the demand for more doctors interested in and comfortable with regenerative medicine surges. ISSCA’s mission is to advance quality and uniformity in regenerative medicine worldwide.
About Global Stem Cells Group:
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement:
Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Release
Global Stem Cells Group Announces Opening of New Research Facility at Marmara University’s Main Campus in Istanbul, Turkey
Collaboration Set to Propel Regenerative Medicine Research and Innovation
Miami, May 20, 2023 – Global Stem Cells Group, a leading provider of regenerative medicine solutions, is thrilled to announce the opening of its state-of-the-art research facility at Marmara University’s Main Campus in Istanbul, Turkey. This collaborative endeavor between Global Stem Cells Group, ReGen (described below), and Marmara University aims to advance research and knowledge in the fields of neurological conditions, autoimmune diseases, and the validation of safety and efficacy of procedures and Cellgenic products.
ReGen, a globally recognized network of clinics and a commercial partner of Global Stem Cells Group, is dedicated to providing cutting-edge cellular therapies that enhance patient well-being. This joint effort between ReGen, Global Stem Cells Group, and Marmara University seeks to drive research and innovation in cell therapy and tissue engineering.
Renowned for its commitment to excellence in education, research, and innovation, Marmara University provides an exceptional foundation for Global Stem Cells Group’s new research facility. With a strong emphasis on interdisciplinary collaboration and forefront research, Marmara University has emerged as a hub of intellectual discovery and academic achievement. The University’s renowned faculty and state-of-the-art infrastructure make it an ideal partner for Global Stem Cells Group in driving advancements in regenerative medicine.
By establishing this collaborative research facility at Marmara University, Global Stem Cells Group plans to access to the university’s wealth of expertise and resources, enabling the organization to undertake extensive clinical studies and groundbreaking research. Together, they will focus on addressing the challenges posed by neurodegenerative diseases and other medical conditions, aiming to develop innovative treatments and therapies that can significantly improve patient outcomes.
“Both Global Stem Cell Group and its commercial partner, ReGen, are thrilled to establish our new research facility in partnership with Marmara University.” Benito Novas, CEO of Global Stem Cells Group, expressed his enthusiasm for the collaboration. “This collaboration holds significant meaning for us, particularly in terms of the Cellgenic brand,” he added.
The Cellgenic product line encompasses a range of point-of-care regenerative medicine products, including autologous and allogeneic therapies, as well as exosomes. After examining the independent testing and validation of these products employed by Marmara University, Global Stem Cell Group is confident in the University’s quality and effectiveness.
The newly inaugurated research facility is expected to serve as a hub for extensive clinical studies on various medical conditions, with a particular focus on neurodegenerative diseases and ailments treatable through cell therapy and tissue engineering. This research is expected to contribute to the advancement of medical knowledge and the development of innovative treatments that have the potential to transform the lives of patients worldwide.
Global Stem Cells Group and its commercial partner, ReGen, extend their gratitude to Marmara University for its unwavering commitment to advancing regenerative medicine research and innovation. The collaboration between Global Stem Cells Group, ReGen, and Marmara University signifies what the parties believe is a significant milestone in the field of regenerative medicine, combining the expertise and resources of three leading institutions to drive breakthrough discoveries and shape the future of healthcare.
For more information about Global Stem Cells Group and its regenerative medicine solutions, please visit https://www.stemcellsgroup.com/.
About Global Stem Cells Group
Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.
About ReGen
ReGen is a renowned network of clinics and commercial partner of Global Stem Cells Group worldwide, offers cutting-edge cellular therapies to enhance the well-being of its patients. ReGen aims to drive research and innovation in cell therapy and tissue engineering together with Global Stem Cells Group and Marmara University.
About Marmara University
Marmara University is a prestigious educational institution renowned for its commitment to excellence in education, research, and innovation. With a strong emphasis on interdisciplinary collaboration and cutting-edge research, Marmara University has emerged as a hub of intellectual discovery and academic achievement. The university’s renowned faculty and state-of-the-art infrastructure make it an ideal partner for Global Stem Cells Group in driving advancements in regenerative medicine.
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Release
The International Society for Stem Cell Application (ISSCA) Announces Speakers for Regenerative Medicine Conference in Pakistan
The International Society of Stem Cell Application has unveiled its acclaimed speakers at their mid-2023 Regenerative Medicine Conference in Pakistan, slated for June 10 and 11 at the prestigious University of Lahore (UOL).
With the invaluable presence of esteemed experts in the field and the latest discoveries and technological advances showcased all in one place, our aim is to provide an enriching experience. This conference promises to cater to the diverse needs of professionals, including those in stem cell research and aesthetic medicine, by offering opportunities for training, access to advanced equipment, and the latest updates on advancements in the field.
Collaborations
Besides the UOL, ISSCA is proud to collaborate with other authoritative institutions in stem cell technology in hosting this landmark conference in Pakistan: The University College of Medicine and Dentistry (UCMD) and the Academy of Aesthetic and Regenerative Medicine (AARM). The event aims to inspire physicians to incorporate regenerative medicine into their practices and enhance global access to these revolutionary services.
The conference will comprise two sections — a theoretical segment and a practical session:
The ISSCA Pakistan Conference Theoretical Segment-Meet the Renowned Expert Speakers
World-class medical experts in regenerative medicine will share their skills and experience during the theoretical session. Their invaluable insights and expertise will provide attendees with cutting-edge knowledge and practical applications of stem cell therapy. They include:
Benito Novas
Leading the team is Benito Novas, the Managing Director of ISSCA and CEO of Global Stem Cells Group. He brings a mastery of building successful medical practices and a passion for continuously developing stem cell research and technologies. He spoke about the collaboration and his vision for the conference and ISSCA, mentioning that “ISSCA’s mission is to share regenerative medicine’s benefits worldwide, supporting patients and physicians in harnessing its power globally.”
Dr. Salih Yildirim
Dr. Yildirim, ISSCA Director of Overseas Operations and head of Middle East Operations, will also speak. Besides having a wealth of knowledge from his studies, he has headed several initiatives in the stem cell field, representing an undoubted authority. Additionally, his prowess stems from overseeing a leading biotechnology supplier of regenerative medicine products; he brings first-hand and in-depth ingenuity that’ll be valuable to the conference.
He enthusiastically expressed his eagerness to share his expertise, saying, “Regenerative medicine is a fast-paced field experiencing exponential growth with ongoing research and product advancements worldwide. We are thrilled to collaborate with esteemed institutions to host this conference.”
Other esteemed speakers include Dr. Fahad Usman, President of the Academy of Aesthetic and Regenerative Medicine and Director Center for Aesthetic Medicine at the University of Lahore (UOL); Dr. Evrim Uçkunkaya, a renowned expert in Plastic, Aesthetic, and Reconstructive Surgery in Turkey; Dr. Hilmi Karadeniz, a reputable clinic owner in Istanbul specializing in arthroscopic and spine surgery, pediatric orthopedics, and Intra-Joint Regenerative Cell Therapy (SVF); Dr. Erdinc Civelek, a Ph.D. candidate at the Health Sciences Istanbul Training and Research Hospital with expertise in stem cell research; and Dr. Serdar Kabataş, General Secretary of the Society of Stem Cell and Cellular Therapies in Turkey with education in Neural Stem Cell (NSC) from Harvard Medical School, who has led several discoveries, publications, and university lectures in the industry.
Dr. Melihcan Sezgiç, a specialist in Plastic, Reconstructive, and Aesthetic Surgery at RegenIC Clinic, ISSCA certificated instructor, and graduate from Ankara University, will also be sharing his expertise at the conference, along with other renowned doctors including Dr. Shehzad Karim Bhatti, an Interventional Radiologist & Pain Management Specialist; Dr. Naveed A Khan, a Plastic Surgeon; Dr. Zaheer Anjum, a Stem Cell & Pain Management Specialist; Dr. M Amir Sohail, an Orthopedic Surgeon; Dr. Sarfraz Ahmad Mughall, an Ophthalmologist; and Dr. Imran Haider Qaisrani, an Orthopedic Surgeon.
The ISSCA Pakistan Conference Practical Segment
The experiential part of the conference will offer participants training on clinical and aesthetic applications of stem cell therapy and the best practices for establishing a safe and efficient medical practice. Physicians and specialists will be treated to state-of-the-art technologies that shape the medical field and the latest knowledge in modern regenerative medicine products.
Final Words About the Conference
The event’s sponsors include Global Stem Cells Group, University College of Medicine and Dentistry (UCMD),Biotrend, and N-Biotek, and we at ISSCA couldn’t express our gratitude enough for this support.
Regenerative medicine is not new; nonetheless, it’s rapidly growing with continuous explorations revealing new protocols and products. The line-up of proficient speakers, high-tech equipment, and hands-on interactions should keep participants updated with the industry’s most recent changes and advancements. It should also empower them to explore more opportunities and offer a chance to be part of a valuable stem cell community. There’s more to learn about ISSCA and advancements in stem cell therapy; visit our website or email us at info@stemcellsgroup.com to stay in the know.
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine.
The mission of the International Stem Cell Certification Agency (ISSCA) is to establish itself as a global leader in regenerative medicine certification, education, research, and training.
ISSCA provides certification training in cities worldwide because it recognizes the importance of standards and certifications in regenerative medicine as a medical specialty. To help more people, both locally and globally, as the demand for more doctors interested in and comfortable with regenerative medicine surges. ISSCA’s mission is to advance quality and uniformity in regenerative medicine worldwide.
About Global Stem Cells Group:
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement:
Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Release